Kallikrein-inhibitor therapies

Details Kallikrein-inhibitor therapies Kallikrein-inhibitor therapies

2007-10-30

2011-10-11

Wen, Sharon (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S015100, C514S016400, C514S012200

Reexamination Certificate

active

08034775

ABSTRACT:
Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.

REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4118481 (1978-10-01), Schnabel
patent: 4153687 (1979-05-01), Schnabel
patent: 4179337 (1979-12-01), Davis et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4609725 (1986-09-01), Brady et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5372933 (1994-12-01), Zamarron
patent: 5441931 (1995-08-01), Sprecher et al.
patent: 5444156 (1995-08-01), Veloso et al.
patent: 5576294 (1996-11-01), Norris et al.
patent: 5677146 (1997-10-01), Sprecher et al.
patent: 5719041 (1998-02-01), Lazarus et al.
patent: 5747449 (1998-05-01), Lasters et al.
patent: 5770568 (1998-06-01), Auerswald et al.
patent: 5780265 (1998-07-01), Dennis et al.
patent: 5786328 (1998-07-01), Dennis et al.
patent: 5795865 (1998-08-01), Markland et al.
patent: 5795954 (1998-08-01), Lazarus et al.
patent: 5800385 (1998-09-01), Demopulos et al.
patent: 5834244 (1998-11-01), Dennis et al.
patent: 5843895 (1998-12-01), Lazarus et al.
patent: 5863893 (1999-01-01), Dennis et al.
patent: 5874407 (1999-02-01), Kelley et al.
patent: 5880256 (1999-03-01), Dennis et al.
patent: 5962266 (1999-10-01), White et al.
patent: 5994125 (1999-11-01), Markland et al.
patent: 6010880 (2000-01-01), Markland et al.
patent: 6013763 (2000-01-01), Braisted et al.
patent: 6057287 (2000-05-01), Markland et al.
patent: 6071723 (2000-06-01), Markland et al.
patent: 6087473 (2000-07-01), Conklin et al.
patent: 6090916 (2000-07-01), Vlasuk et al.
patent: 6103499 (2000-08-01), Markland et al.
patent: 6113896 (2000-09-01), Lazarus et al.
patent: 6159938 (2000-12-01), Gyorkos et al.
patent: 6180607 (2001-01-01), Davies et al.
patent: 6261279 (2001-07-01), Demopulos et al.
patent: 6306884 (2001-10-01), Buckman et al.
patent: 6333402 (2001-12-01), Markland et al.
patent: 6423498 (2002-07-01), Markland et al.
patent: 7064107 (2006-06-01), Ladner et al.
patent: 7153829 (2006-12-01), Ladner et al.
patent: 7166576 (2007-01-01), Cicardi et al.
patent: 7235530 (2007-06-01), Blair et al.
patent: 7276480 (2007-10-01), Ladner et al.
patent: 2001/0027180 (2001-10-01), Isaacs
patent: 2003/0113726 (2003-06-01), Tsuchihashi
patent: 2004/0038893 (2004-02-01), Ladner et al.
patent: 2004/0053206 (2004-03-01), Cicardi et al.
patent: 2004/0171794 (2004-09-01), Ladner et al.
patent: 2005/0164928 (2005-07-01), Ladner et al.
patent: 2006/0069020 (2006-03-01), Blair et al.
patent: 2007/0049522 (2007-03-01), Ladner et al.
patent: 2007/0213275 (2007-09-01), Clark et al.
patent: 2007/0249807 (2007-10-01), Ladner et al.
patent: 2008/0064637 (2008-03-01), Ladner et al.
patent: 2008/0076712 (2008-03-01), Ladner et al.
patent: 2008/0131426 (2008-06-01), Ladner et al.
patent: 2008/0152656 (2008-06-01), Ladner et al.
patent: 2008/0188409 (2008-08-01), Blair et al.
patent: 2008/0200646 (2008-08-01), Ladner et al.
patent: 2008/0221031 (2008-09-01), Blair et al.
patent: 2008/0226655 (2008-09-01), Ladner et al.
patent: 2008/0260752 (2008-10-01), Ladner et al.
patent: 2009/0082267 (2009-03-01), Ladner et al.
patent: E 275 583 (2005-04-01), None
patent: 2 180 950 (2005-03-01), None
patent: 695 33 472 (2006-01-01), None
patent: 0 285 123 (1988-10-01), None
patent: 0 621 871 (1991-07-01), None
patent: 0 621 870 (1997-05-01), None
patent: 0 739 355 (2004-08-01), None
patent: 1 484 339 (2004-08-01), None
patent: WO 89/10374 (1989-11-01), None
patent: WO9206111 (1992-04-01), None
patent: WO9309233 (1993-05-01), None
patent: WO 93/14120 (1993-07-01), None
patent: WO 93/14121 (1993-07-01), None
patent: WO 93/14122 (1993-07-01), None
patent: WO 95/18830 (1995-07-01), None
patent: 95/21601 (1995-08-01), None
patent: WO 95/21601 (1995-08-01), None
patent: 00/14235 (2000-03-01), None
patent: WO0179480 (2001-10-01), None
patent: WO03066824 (2003-08-01), None
patent: WO 03/103475 (2003-12-01), None
patent: WO 2004/019968 (2004-11-01), None
patent: 2005021557 (2005-03-01), None
patent: 2006066878 (2006-06-01), None
patent: 2006089005 (2006-08-01), None
patent: 2009026334 (2009-02-01), None
Han, Eun D. Reversal of the Increased Vascular Permeability in C1 Inhibitor Deficient Mice: Therapeutic Approaches, International Immunopharmacology 2(9):1315 Abstract 176 (2002).
Han, Eun D. et al., Increased Vascular Permeability in C1 Inhibitor-Deficient Mice Mediated by the Bradykinin Type 2 Receptor, J. Clinical Investigation 109(8):1057-1063 (2002).
Gonzalez-Quevedo, T. et al., The Synthetic Kunitz Domain Protein DX88 to Treat Angioedema in Patients with Hereditary Angioedema, International Immunopharmacology 2(9):1318 Abstract 205 (2002).
Lumry et al, Interim Results of EDEMA2, A Multicenter, Open-Label, Repeat-Dosing Study of Intravenous and Subcutaneous Administration of Ecallantide (DX-88) in Hereditory Angioedema. J. Allergy and Clinical Immunology 117(2)(Suppl. 1):S179 Abstract 699 (2006).
Rossi, E. et al., The Synthetic Peptide DX88 Binds to Endothelial Cells In Vitro and Retains the Inhibitory Activity on Kallikrein, International Immunopharmacology 2(9):1313, Abstract 142 (2002).
International Search Report received in PCT/US07/63703, dated Dec. 21, 2007.
Communication received in EP Patent Application 03757339.1, dated Apr. 23, 2008.
Extended European Search Report dated Apr. 2, 2009, which includes the European Search Report and the European Search Opinion.
Adelman, et al., Proteolysis of Platelet Glycoprotein Ib by Plasmin Is Facilitated by Plasmin Lysine-Binding Regions,Blood, vol. 68 (6): 1280-1284, (Dec. 1986).
Albrecht, et al., Kunitz-Type Proteinase Inhibitors Derived by Limited Proteolysis of the Inter-α-Trypsin Inhibitors From several Mammalian Sera,Hoppe-Seyler's Z. Physiol. Chem., vol. 364: 1697-1702, (Dec. 1983).
Albrecht, et al.., Elastase Inhibition by the Inter-α-Trypsin Inhibitor and Derived Inhibitors of Man and Cattle,Hoppe-Seyler's Z. Physiol. Chem., vol. 364: 1703-1708, (Dec. 1983).
Anba, et al., Improving the Stability of a Foreign Protein in the Periplasmic Space ofEscherichia coli, Biochimie, vol. 70(6): 727-733, (1988).
Angliker, et al., The Synthesis of Lysylflouromethanes and their Properties as Inhibitors of Trypsin, Plasmin and Cathepsin B,Biochemistry, vol. 241 (3): 871-875, (Jan. 1987).
Atherton, et al., Peptide Synthesis. Part 21Procedures for Solid Phase Synthesis using Nα-Fluorenylmethycarbonylamino-acids on Polyamide Supports. Synthesis of Substance P and of Acyl Carrier Protein 65-74 Decapeptide,J Chem Soc Perkins Trans, vol. 1: 538-546, (1981).
Auerswald et al., Expression, Isolation and Characterization of Recombinant [Arg15, Glu52] Aprotinin,Biol Chem Hoppe-Seyler, vol. 369 (supplement): 27-35, (May 1988).
Baba, M., et al., States of Tyrosyl Residues and Circular Dichroism of Kunitz Trypsin Inhibitor,J. Biochem. (Tokyo), vol. 65 (1): 113-121, (1969).
Balduyck, et al., Human Urinary Proteinase Inhibitor: Inhibitory Properties and Interaction with Bovine Trypsin,Biol Chem Hoppe-Seyler, vol. 366: 9-14, (Jan. 1985).
Baneyx and Georgiou, In Vivo Degradation of Secreted Fusion Proteins by theEscherichia coliOuter Membrane Protease OmpT,J. Bacterial., vol. 172 (1): 491-494, (Jan. 1990).
Baneyx and Georgiou, Construction and Characterization ofEscherichia coliStrains Deficient in Multiple Secreted Proteases: Protease III Degrades High-Molecular-Weight Substrates In Vivo,J Bacteriol., vol. 173 (8): 2696-2703, (Apr. 1991).
Berndt, et al., Designed Replacement of an Internal Hydration Water Molecule in BPTI: Structural and Functional Implications of a Glycine-to-Serine Mutation,Biochemistry, vol. 32: 4564-4570, (1993).
Bhoola et al., Bioregulation of Kinins: Kallikreins, Kininogens and Kininases,Pharmacological Reviews, vol. 44 (1): 1-80, (1992).
Browne, et al., Expression of Recombinant Human Plasminogen and Aglycoplasminogen in

Affiliated with

Also associated with

Rating

Kallikrein-inhibitor therapies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Kallikrein-inhibitor therapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kallikrein-inhibitor therapies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4286883